Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 simultaneously alleviate high-fat diet-induced colitis, endotoxemia, liver steatosis, and obesity in mice.

Long-term feeding of a high-fat diet (HFD) induces endotoxemia and gastrointestinal inflammation by disturbing gut microbiota composition and membrane permeability, resulting in the acceleration of obesity. Some probiotics exhibit anti-inflammatory effects in vitro and in vivo. Therefore, we hypothesized that anti-inflammatory probiotics could lead to the simultaneous attenuation of endotoxemia, liver steatosis, obesity, and colitis in mice with HFD-induced obesity. Herein, we examined whether Lactobacillus plantarum LC27 and/or Bifidobacterium longum LC, which significantly suppressed NF-κB activation in lipopolysaccharide- or fecal lysate-stimulated Caco-2 cells, could simultaneously alleviate liver steatosis and colitis in mice with HFD-induced obesity. Oral administration of LC27, LC67, or their (3:1) mixture (LM) reduced HFD-induced aspartate transaminase, alanine transaminase, triglyceride, total cholesterol, and lipopolysaccharide levels in the blood and liver. Their treatments also suppressed HFD-induced NF-κB activation and increased AMP-activated protein kinase (AMPK) activation and claudin-1 and occludin expression in the liver and colon. Moreover, LC27, LC67, or LM treatment reduced HFD-induced Firmicutes and Proteobacteria populations in gut microbiota and fecal lipopolysaccharide production. The hypothesis was supported by the findings that anti-inflammatory LC27 and/or LC67 simultaneously alleviated liver steatosis, obesity, and colitis by regulating NF-κB and AMPK activation through the inhibition of gut microbiota lipopolysaccharide production.